Citations

Clear

1526 citation(s) found for "Sun, Yu".

Effect of ApoE isoforms on mitochondria in Alzheimer disease
Yin, Junxiang , Reiman, Eric M. , Beach, Thomas G. , Nielsen, Megan , Caselli, Richard J. , Shi, Jiong , Shi, Jiong , Serrano, Geidy E. , Sabbagh, Marwan Noel

Mayo Clinic

Neurology | May 27, 2020 | Volume: 94 | Issue: 23 | Pages: No page available

10.1212/wnl.0000000000009582 | PMID 32457210 Get It

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
Mandrekar, Sumithra J. , Oxnard, Geoffrey R. , Hillman, Shauna L., Sun, Zhuoxin , Gray, Jhanelle E. , Malik, Shakun , Mooney, Margaret , Jänne, Pasi A. , Stinchcombe, Tom, Sands, Jacob , Kozono, David , Dahlberg, Suzanne E. , Chaft, Jamie E. , Govindan, Ramaswamy , Gerber, David E. , Vokes, Everett E. , Kelly, Karen , Ramalingam, Suresh S. , Stinchcombe, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: TPS9077-TPS9077

10.1200/jco.2020.38.15_suppl.tps9077 Get It

TPS9077 Background: ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a clinical trial platform of the National Cancer Institute that offers biomarker analysis for high-risk resected non-small cell lung cancer (NSCLC) to support randomized trials of novel adjuvant therapies within the National Clinical Trials Network (NCTN). EA5142, a trial of adjuvant nivolumab for patients (pts) without EGFR / ALK alterations, has completed enrollment. Given the survival benefit seen with 1st-line chemo-immunotherapy (chemo-IO) for advanced NSCLC without EGFR / ALK alterations, there was compelling rationale for the launch of a trial offering concurrent immunotherapy with adjuvant chemo. Here we report updated enrollment to ALCHEMIST as of Jan 14, 2020. Methods: ALCHEMIST includes a screening trial (A151216, 5362 registered) that enrolls pts with completely resected clinical stage IB (≥4 cm)–IIIA (per AJCC 7) NSCLC. Tissue and blood are collected, biomarker testing includes EGFR sequencing, ALK FISH and PD-L1 IHC. 733 active sites are enrolling across the NCTN. Pts with EGFR mutations may enroll to adjuvant erlotinib vs observation (A081105, 352 randomized); those with ALK fusions may enroll to adjuvant crizotinib vs observation (E4512, 99 randomized). A trial offering adjuvant nivolumab vs observation regardless of PD-L1 status (EA5142, 935 randomized) recently completed enrollment. To support ongoing investigation of adjuvant immunotherapy, ALCHEMIST is adding A081801 (opens spring 2020). Pts will be randomized to one of 3 arms: chemo-IO with pembrolizumab during and after chemo vs sequential chemo followed by pembrolizumab vs chemo alone. Pts with pathological N2 nodes are eligible and can undergo postoperative radiotherapy after completing chemo. Pts are eligible if enrolled to A151216, negative for EGFR and ALK alterations, and with PD-L1 testing completed (required for stratification). Local testing for EGFR, ALK and PD-L1 will be accepted for enrollment; central testing will not delay randomization. Pts may not have received any therapy except surgery for the lung cancer and must be age >18, Eastern Cooperative Oncology Group performance status 0-1, have no active autoimmune disease requiring systemic treatment within 2 years, must not be pregnant or nursing, have no active second malignancy within 3 years and meet standard organ function values. By building off the ongoing ALCHEMIST platform, we hope to facilitate rapid enrollment to A081801 across participating NCTN sites. Clinical trial information: NCT02194738.
Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials.
Malone, Shawn , Roy, Soumyajit , Grimes, Scott, Eapen, Libni , Malone, Julia, Craig, Julia , Dess, Robert T. , Schipper, Matthew J. , Michalski, Jeff M. , Pisansky, Thomas M. , Feng, Felix Y. , Shipley, William U. , Roach, Mack , Lawton, C.A., Dess, Robert T , Spratt, Daniel E. , Morgan, Scott C. , Jackson, Will , Lee, W. Robert , Sandler, Howard M. , Sun, Yilun

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 5584-5584

10.1200/jco.2020.38.15_suppl.5584 Get It

5584 Background: The timing of systemic therapy in relation to radiotherapy (RT) is important in most malignancies. In contrast, androgen deprivation therapy (ADT) has largely been investigated in relation to its duration rather than its sequencing with RT. Herein, we conduct the first combined individual patient analysis of two phase III randomized trials to determine the optimal timing of ADT with RT in localized prostate cancer (PCa). Methods: Individual patient data was obtained from the Malone et al trial (JCO 2019), which randomized patients to receive neoadjuvant/concurrent or concurrent/adjuvant ADT for 6 months with prostate only RT. This was combined with the prostate only RT arms of RTOG 9413 that randomized patients to 4 months of neoadjuvant/concurrent or adjuvant ADT. The neoadjuvant/concurrent arms of both trials were combined into the “neoadjuvant” group, and the concurrent/adjuvant (Malone) and adjuvant arm (RTOG 9413) were combined in the “adjuvant” group. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Cumulative incidence of distant metastasis (DM), PCa-specific mortality (PCSM) and biochemical failure (BF) were calculated using the Fine-Gray method with non-PCa deaths as competing events. Late genitourinary (GU) and gastrointestinal (GI) toxicity are also reported. Results: The median follow-up was 14.9 years (yrs) and 1065 patients were included (n=531 neoadjuvant, 534 adjuvant). Groups were well balanced for all baseline characteristics. Adjuvant ADT was superior to neoadjuvant ADT in terms of BF (15yr: 33% vs 43%, HR: 1.37 (95%CI: 1.12-1.68), p=0.002), DM (15yr: 12% vs 18%, HR: 1.40 (95%CI: 1.00-1.95), p=0.04), and PFS (15yr: 36% vs 29%, HR: 1.25 (95%CI: 1.07-1.47), p=0.01). Adjuvant ADT yielded lower PCSM (15yr: 15% vs 20%, HR: 1.29 (95%CI: 0.95-1.75), p=0.10), but did not reach statistical significance. This approached statistical significance in high risk PCa (HR 1.39 (95%CI 1.00-1.93), p=0.053). OS was not significantly different between arms (15yr: 39% vs 34%, HR: 1.11 (95%CI: 0.95-1.30), p=0.20). There was no significant difference in either late grade ≥3 GI (p=0.21) or GU (p=0.98) toxicity. Conclusions: We demonstrate for the first time that sequencing of ADT with RT significantly impacts long-term oncologic outcomes in localized PCa, favoring an adjuvant rather than neoadjuvant approach, without increasing late toxicity. This data has important implications to ongoing and future clinical trial design. Clinical trial information: NCT00769548 .
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia
Zhou, Yalu, Han, Cuijuan , Wang, Eric , Lorch, Adam H., Serafin, Valentina , Cho, Byoung-Kyu , Gutierrez-Diaz, Blanca T. , Calvo, Julien , Fang, Celestia, Khodadadi‐Jamayran, Alireza , Tabaglio, Tommaso , Marier, Christian, Kuchmiy, Anna , Sun, Limin , Yacu, George, Filip, Szymon K. , Jin, Qi , Takahashi, Yoh-hei, Amici, David R. , Rendleman, Emily J. , Rawat, Radhika , Paganin, Maddalena , Kandela, Irawati , Politanska, Yuliya , Palhais, Bruno , Vlierberghe, Pieter Van , Taghon, Tom , Aifantis, Iannis , Goo, Young Ah , Guccione, Ernesto , Heguy, Adriana , Tsirigos, Aristotelis , Wee, Keng Boon , Mishra, Rama K. , Pflumio, Françoise , Accordi, Benedetta , Ntziachristos, Panagiotis , Jin, Qi , Taghon, Tom , Goo, Young Ah , Tsirigos, Aristotelis , Basso, Giuseppe , Khodadadi-Jamayran, Alireza , Van Vlierberghe, Pieter , Gutierrez Diaz, Blanca , Cho, Byoung-Kyu , Han, Cuijuan , Serafin, Valentina , Jin, Qi , Takahashi, Yoh-Hei, Bresolin, Silvia , Zhang, Cheng , Li, Hu , Abdala‐Valencia, Hiam , Mendillo, Marc L. , Zhu, Ping, Basso, Giuseppe , Jin, Qi

Mayo Clinic

Cancer Discovery | May 22, 2020 | Volume: 10 | Issue: 9 | Pages: 1388-1409

10.1158/2159-8290.cd-19-1436 | PMID 32444465 Get It

Abstract Splicing alterations are common in diseases such as cancer, where mutations in splicing factor genes are frequently responsible for aberrant splicing. Here we present an alternative mechanism for splicing regulation in T-cell acute lymphoblastic leukemia (T-ALL) that involves posttranslational stabilization of the splicing machinery via deubiquitination. We demonstrate there are extensive exon skipping changes in disease, affecting proteasomal subunits, cell-cycle regulators, and the RNA machinery. We present that the serine/arginine-rich splicing factors (SRSF), controlling exon skipping, are critical for leukemia cell survival. The ubiquitin-specific peptidase 7 (USP7) regulates SRSF6 protein levels via active deubiquitination, and USP7 inhibition alters the exon skipping pattern and blocks T-ALL growth. The splicing inhibitor H3B-8800 affects splicing of proteasomal transcripts and proteasome activity and acts synergistically with proteasome inhibitors in inhibiting T-ALL growth. Our study provides the proof-of-principle for regulation of splicing factors via deubiquitination and suggests new therapeutic modalities in T-ALL. Significance: Our study provides a new proof-of-principle for posttranslational regulation of splicing factors independently of mutations in aggressive T-cell leukemia. It further suggests a new drug combination of splicing and proteasomal inhibitors, a concept that might apply to other diseases with or without mutations affecting the splicing machinery. This article is highlighted in the In This Issue feature, p. 1241
Enhanced nerve cell proliferation and differentiation on electrically conductive scaffolds embedded with graphene and carbon nanotubes
Sun, Yuan , Liu, Xifeng , George, Matthew N. , Park, Sungjo , Gaihre, Bipin , Lu, Lichun , Miller, A. Lee , Miller, Alan Lee , Terzic, André

Mayo Clinic

Journal of Biomedical Materials Research Part A | May 22, 2020 | Volume: 109 | Issue: 2 | Pages: 193-206

10.1002/jbm.a.37016 | PMID 32441388 Get It

AbstractConduits that promote nerve regeneration are currently of great medical concern, particularly when gaps exist between nerve endings. To address this issue, our laboratory previously developed a nerve conduit from biodegradable poly(caprolactone fumarate) (PCLF) that supports peripheral nerve regeneration. The present study improves upon this work by further developing an electrically conductive, positively charged PCLF scaffold through the incorporation of graphene, carbon nanotubes (CNTs), and [2‐(methacryloyloxy)ethyl]trimethylammonium chloride (MTAC) (PCLF–Graphene–CNT–MTAC) using ultraviolet (UV) induced photocrosslinking. Scanning electron microscopy, transmission electron microscopy, and atomic force microscopy were used to assess the incorporation of CNTs and graphene into PCLF–Graphene–CNT–MTAC scaffolds, which displayed enhanced surface roughness and reduced electrochemical impedance when compared to neat PCLF. Scaffolds with these surface modifications also showed improved growth and differentiation of rat pheochromocytoma 12 cells in vitro, with enhanced cell growth, neurite extension, and cellular migration. Furthermore, an increased number of neurite protrusions were observed when the conduit was electrically stimulated. These results show that the electrically conductive PCLF–Graphene–CNT–MTAC nerve scaffolds presented here support the cellular behaviors that are critical for nerve regeneration, ultimately making this material an attractive candidate for regenerative medicine applications.
Urinary Extracellular Vesicles as Biomarkers of Kidney Disease: From Diagnostics to Therapeutics
Sun, In O , Lerman, Lilach O.

Mayo Clinic

Diagnostics | May 18, 2020 | Volume: 10 | Issue: 5 | Pages: 311

10.3390/diagnostics10050311 | PMID 32429335 Get It

Cell-derived extracellular vesicles (EVs) can be isolated from various body fluids, including urine. Urinary EVs have gained important recognition as potential diagnostic biomarkers in renal disease since their cargo includes nucleic acids, proteins, and other cellular components, which likely mirror the physiological and possibly pathophysiological state of cells along the nephron. Accumulating evidence highlights the feasibility of using EVs as biomarkers for diagnostic, prognostic, and therapeutic purposes in several forms of renal disease, such as acute kidney injury, glomerulonephritis, and renal transplantation. Additionally, exogenous delivery of EVs released in vitro by cells in culture may have salutary benefits for renal diseases. In this review, we introduce recent studies that attempt to identify urinary EVs as candidate biomarkers for human kidney diseases and consider their potential implication as a therapeutic option in key kidney diseases.
Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location
Labadie, Julia , Harrison, Tabitha A. , Banbury, Barbara L. , Amtay, Efrat L, Bernd, Sonja, Brenner, Hermann , Campbell, Peter T. , Cao, Yin , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Gunter, Marc J. , Hoffmeister, Michael , Moreno, Vı́ctor , Murphy, Neil , Phipps, Amanda I. , Slattery, Martha L. , Thibodeau, Stephen N. , Guelpen, Bethany Van , Zaidi, Syed Hassan Ejaz , Peters, Ulrike , Labadie, Julia D , Banbury, Barbara , Campbell, Peter T , Cao, Yin , Chang-Claude, Jenny , English, Dallas R , Gunter, Marc J , Hoffmeister, Michael , Jenkins, Mark A , Milne, Roger L , Moreno, Victor , Ogino, Shuji , Sakoda, Lori C , Sun, Wei , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Murphy, Neil , Buchanan, Daniel D. , Chan, Andrew T. , English, Dallas R. , Giles, Graham G. , Hsu, Li , Jenkins, Mark A. , Lin, Yi , Milne, Roger L. , Sakoda, Lori C. , Southey, Melissa C. , Sun, Wei , Newcomb, Polly A.

Mayo Clinic

JNCI Cancer Spectrum | May 13, 2020 | Volume: 4 | Issue: 5 | Pages: No page available

10.1093/jncics/pkaa042 | PMID 32923935 Get It

AbstractBackgroundPostmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly defined tumor subtypes and tumor location.MethodsWe pooled data on tumor subtypes (microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, pathway: adenoma-carcinoma, alternate, serrated), tumor location (proximal colon, distal colon, rectum), and HT use among 8220 postmenopausal women (3898 CRC cases and 4322 controls) from 8 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CIs) for the association of ever vs never HT use with each tumor subtype compared with controls. Models were adjusted for study, age, body mass index, smoking status, and CRC family history. All statistical tests were 2-sided.ResultsAmong postmenopausal women, ever HT use was associated with a 38% reduction in overall CRC risk (OR =0.62, 95% CI = 0.56 to 0.69). This association was similar according to microsatellite instability, CpG island methylator phenotype and BRAF or KRAS status. However, the association was attenuated for tumors arising through the serrated pathway (OR = 0.81, 95% CI = 0.66 to 1.01) compared with the adenoma-carcinoma pathway (OR = 0.63, 95% CI = 0.55 to 0.73; Phet =.04) and alternate pathway (OR = 0.61, 95% CI = 0.51 to 0.72). Additionally, proximal colon tumors had a weaker association (OR = 0.71, 95% CI = 0.62 to 0.80) compared with rectal (OR = 0.54, 95% CI = 0.46 to 0.63) and distal colon (OR = 0.57, 95% CI = 0.49 to 0.66; Phet =.01) tumors.ConclusionsWe observed a strong inverse association between HT use and overall CRC risk, which may predominantly reflect a benefit of HT use for tumors arising through the adenoma-carcinoma and alternate pathways as well as distal colon and rectal tumors.
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
Brazauskas, Ruta , Tecca, Heather R. , Bo‐Subait, Stephanie, Buchbinder, David , Battiwala, Minoo, Phelan, Rachel , Broglie, Larisa , Abraham, Allistair , Keating, Amy K. , Daly, Andrew , Wirk, Baldeep , Alter, Blanche P. , Üstün, Celalettin , Freytes, César O. , Beitinjaneh, Amer , Duncan, Christine , Copelan, Edward A. , Hildebrandt, Gerhard , Murthy, Hemant S. , Auletta, Jeffery J. , Page, Kristin , Vrooman, Lynda M. , Norkin, Maxim , Byrne, Michael , Kamani, Naynesh , Rezvani, Andrew R. , Farhadfar, Nosha , Mehta, Parinda A. , Hematti, Peiman , Shaw, Peter J. , Kamble, Rammurti T., Schears, Raquel M. , Hayashi, Robert J. , Mayo, Samantha , Rotz, Seth J. , Badawy, Sherif M. , Ganguly, Siddhartha , Pavletic, Steven Z. , Prestidge, Tim , Inamoto, Yoshihiro , Shaw, Bronwen E. , Satwani, Prakash , Battiwalla, Minoo , Schears, Raquel, Murthy, Hemant S , Badawy, Sherif M , Broglie, Larisa A , Battiwalla, Minoo , Auletta, Jeffery J , Hematti, Peiman , Kahn, Justine M , Flowers, Mary E.D. , Savani, Bipin N. , George, Biju , Lazarus, Hillard M. , Myers, Kasiani , Williams, Kirsten M. , Díaz, Miguel Ángel , Bhatt, Neel S. , Olsson, Richard F. , Gale, Robert Peter , Chhabra, Saurabh , Nishihori, Taiga , Agrawal, Vaibhav , Hogan, William J.

Mayo Clinic

Blood Advances | May 12, 2020 | Volume: 4 | Issue: 9 | Pages: 2084-2094

10.1182/bloodadvances.2019000839 | PMID 32396620 Get It

Abstract We examined the risk of subsequent neoplasms (SNs) and late mortality in children and adolescents undergoing allogeneic hematopoietic cell transplantation (HCT) for nonmalignant diseases (NMDs). We included 6028 patients (median age, 6 years; interquartile range, 1-11; range, <1 to 20) from the Center for International Blood and Marrow Transplant Research (1995-2012) registry. Standardized mortality ratios (SMRs) in 2-year survivors and standardized incidence ratios (SIRs) were calculated to compare mortality and SN rates with expected rates in the general population. Median follow-up of survivors was 7.8 years. Diagnoses included severe aplastic anemia (SAA; 24%), Fanconi anemia (FA; 10%), other marrow failure (6%), hemoglobinopathy (15%), immunodeficiency (23%), and metabolic/leukodystrophy syndrome (22%). Ten-year survival was 93% (95% confidence interval [95% CI], 92% to 94%; SMR, 4.2; 95% CI, 3.7-4.8). Seventy-one patients developed SNs (1.2%). Incidence was highest in FA (5.5%), SAA (1.1%), and other marrow failure syndromes (1.7%); for other NMDs, incidence was <1%. Hematologic (27%), oropharyngeal (25%), and skin cancers (13%) were most common. Leukemia risk was highest in the first 5 years posttransplantation; oropharyngeal, skin, liver, and thyroid tumors primarily occurred after 5 years. Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95% CI, 8.9-13.9) compared with the general population. We report excellent long-term survival and low SN incidence in an international cohort of children undergoing HCT for NMDs. The risk of SN development was highest in patients with FA and marrow failure syndromes, highlighting the need for long-term posttransplantation surveillance in this population.
Differential effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
Su, L. Joseph , Zhang, Jiahao , Jiang, Nanhui, Li, Juan , Qin, Xie, Huang, Rong , Liu, fang, Feng, Ying , Lu, Qiaofa , Peng, Zhiyong , su, Lianjiu, Yang, Jie , Li, He , Kashani, Kianoush , Liu, Rengyun

Mayo Clinic

No container title available | May 11, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.158921625.56758049 Get It

AIMS To report the major characteristics and clinical outcomes of COVID-19 patients treated with ACE inhibitors and ARBs and compare the different effects of the two drugs for outcomes of COVID-19 patients. METHODS This is a retrospective, two-center case series of 198 consecutive COVID-19 patients with a history of hypertension. RESULTS Among 198 patients, 58 (29.3%) and 16 (8.1%) were on were on ARB and ACEI, respectively. Patients who were on ARB or ACEI/ARB had a significantly lower rate of severe illness and ARDS when compared with patients treated with ACEI alone or not receiving RAAS blocker (P<0.05). The Kaplan-Meier survival curve showed that patients with ARB in their antihypertensive regimen had a trend towards a higher survival rate when compared with individuals without ARB (adjusted hazard ratio, 0.27; 95% CI, 0.07-1.02; P=0.054). The occurrence rates of severe illness, ARDS, and death were similar in the two groups regardless of receiving ACEI. The Cox-regression analysis to compared ACEI vs. ARB groups showed a significantly lower mortality rate in the ARB group (adjusted hazard ratio, 0.03; 95% CI, 0.00-0.58; P=0.02). CONCLUSIONS Our data may provide some evidence of using ARB, but not ACEI, was associated with a reduced rate of severe illness and ARDS, indicating their potential protective impact in COVID-19. Further large sample sizes and multiethnic populations are warranted to confirm our findings.
SUN-LB135 Estrogen Receptor Beta Inhibits NFkB Signaling to Inhibit Triple Negative Breast Cancer
Aspros, Kirsten G. M. , Subramaniam, Malayannan , Ye, Zhenqing, Hawse, John R. , Sun, Zhifu , Ingle, James N. , Goetz, Matthew P.

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.2252 Get It

Abstract Triple Negative Breast Cancer (TNBC) affects approximately 15-20% of BC patients, yet accounts for a disproportionately higher rate of BC morbidity and mortality, in part due to lack of targeted therapies. We have shown that estrogen receptor beta (ERβ) is expressed in approximately 20% of TN breast tumors and that ligand-mediated activation of ERβ with estradiol (E2) or ERβ-selective agonists decreases tumor cell proliferation, invasion and migration in vitro and in vivo. Therefore, we aimed to elucidate the mechanisms by which ERβ elicits its anti-cancer effects in TNBC. RNAseq analysis of ERβ-expressing MDA-MB-231 cells demonstrated that ERβ significantly downregulates NFκB signaling in the presence of E2. ChIPseq for ERβ in these cells revealed that ERβ primarily associated with estrogen response elements, but 12% of all ERβ binding sites were located at NFκB consensus motifs. Using an NFκB reporter construct and qPCR, ERβ was shown to block TNFα-mediated induction of NFκB signaling and NFκB target gene expression. RNAseq analysis of MDA-MB-231-ERβ cells treated with TNFα or E2+TNFα revealed substantial global inhibition of TNFα regulated genes in the presence of E2. ChIPseq for NFκB demonstrated that ERβ significantly alters NFκB’s cistrome whereby it can both diminish NFκB binding and redistribute NFκB throughout the genome. ChIPseq also demonstrated that ligand-mediated activation of ERβ significantly diminished an activating histone mark (H3K27Ac) at many of these NFκB target genes while enhancing a repressive mark (H3K27Me3). The addition of H3K27Me3 at these loci was shown to occur through the recruitment of the histone methyltransferase, EZH2. Drug-mediated blockade of EZH2 activity reversed suppression of NFκB target gene expression by ERβ. Knockdown of NFκB or Mutation of ERβ’s DNA binding domain rendered ERβ incapable of associating with DNA, recruiting EZH2, methylating NFκB target gene loci, repressing NFκB target gene expression and inhibiting proliferation. Interestingly, ERβ was shown to elicit more potent anti-cancer effects in TNBC cells expression a constitutively active form of NFκB. These finding suggest that a primary mechanism by which ERβ functions as a tumor suppressor is through inhibition of NFκB pathway activity. Our studies have also revealed that ERβ functions as a molecular switch for EZH2 and repurposes it for tumor suppressive activities, as EZH2 has previously been reported to enrich NFκB signaling in TNBC. These findings could address the paradox that high EZH2 expression is associated with worse TNBC patient outcomes, while high H3K27Me3 expression is associated with improved patient outcomes. Currently, a Mayo Clinic Breast Cancer SPORE prospective phase II clinical trial is underway to investigate the efficacy of estradiol for the treatment of metastatic ERβ+TNBC and to further evaluate the cross-talk between ERβ, EZH2 and NFκB signaling.